Proteomic profiling of non-obese type 2 diabetic skeletal muscle

EDEL MULLEN and KAY OHLENDIECK

Department of Biology, National University of Ireland, Maynooth, County Kildare, Ireland

Received October 22, 2009; Accepted November 24, 2009

DOI: 10.3892/ijmm_00000364

Abstract. Abnormal glucose handling has emerged as a major clinical problem in millions of diabetic patients worldwide. Insulin resistance affects especially one of the main target organs of this hormone, the skeletal musculature, making impaired glucose metabolism in contractile fibres a major feature of type 2 diabetes. High levels of circulating free fatty acids, an increased intramyocellular lipid content, impaired insulin-mediated glucose uptake, diminished mitochondrial functioning and an overall weakened metabolic flexibility are pathobiochemical hallmarks of diabetic skeletal muscles. In order to increase our cellular understanding of the molecular mechanisms that underlie this complex diabetes-associated skeletal muscle pathology, we initiated herein a mass spectrometry-based proteomic analysis of skeletal muscle preparations from the non-obese Goto-Kakizaki rat model of type 2 diabetes. Following staining of high-resolution two-dimensional gels with colloidal Coomassie Blue, 929 protein spots were detected, whereby 21 proteins showed a moderate differential expression pattern. Decreased proteins included carbonic anhydrase, 3-hydroxyisobutyrate dehydrogenase and enolase. Increased proteins were identified as monoglyceride lipase, adenylate kinase, Cu/Zn superoxide dismutase, phosphoglucomutase, aldolase, isocitrate dehydrogenase, cytochrome c oxidase, small heat shock Hsp27/B1, actin and 3-mercaptoxypruvate sulfurtransferase. These proteomic findings suggest that the diabetic phenotype is associated with a generally perturbed protein expression pattern, affecting especially glucose, fatty acid, nucleotide and amino acid metabolism, as well as the contractile apparatus, the cellular stress response, the anti-oxidant defense system and detoxification mechanisms. The altered expression levels of distinct skeletal muscle proteins, as documented in this study, might be helpful for the future establishment of a comprehensive biomarker signature of type 2 diabetes. Reliable markers could be used for improving diagnostics, monitoring of disease progression and therapeutic evaluations.

Introduction

The number of diabetic patients suffering from severe metabolic disturbances and glucotoxic complications is rapidly increasing worldwide and the incidence of diabetes is approaching endemic proportions (1). Type 2 diabetes mellitus represents a highly complex and heterogeneous disease that is influenced by both genetic and environmental factors (2). A modern sedentary lifestyle and obesity-associated metabolic complications clearly play an essential role in disease progression (3). The principal features of type 2 diabetes are an abnormal sensitivity of peripheral tissues to insulin and decreased levels of hormone secretion. Insulin resistance affects especially skeletal muscles, since contractile fibres are responsible for most of the insulin-triggered whole body glucose disposal. This makes impaired insulin signaling and disturbed glucose metabolism in muscle tissues a striking feature of type 2 diabetes (4).

In contrast to the well-established cardiomyopathic pathology of diabetes (5), it is poorly understood how abnormal tissue sensitivity to insulin causes decreased skeletal muscle strength (6), especially in older individuals with type 2 diabetes (7). Besides impaired insulin-mediated glucose uptake, fatty acid metabolism also has a profound influence on diabetic side effects. Type 2 diabetes is associated with high levels of circulating free fatty acids, an increased intramyocellular lipid content, diminished mitochondrial functioning and an overall weakened metabolic flexibility in the skeletal musculature, as reviewed by Phielix and Mensink (8). Lipid deposition in non-adipose tissues, such as skeletal muscle, has been shown to be related to insulin resistance, whereby possibly the accumulation of triacylglycerol does not directly influence insulin signaling but indirectly via its lipid metabolites (9).

In order to further our molecular understanding of diabetes-related abnormalities in skeletal muscles, mass spectrometry-based proteomics suggests itself as an ideal analytical tool for performing global screening approaches to determine potential alterations in protein expression levels (10). As recently reviewed by Sandsten and Ortsaeter (11), numerous proteomic programmes have been initiated to unravel the complex pathobiocchemical mechanisms that underlie diabetes, focusing especially on the pancreas, blood, adipose tissue and the liver. In analogy, here we carried out the proteomic profiling of crude skeletal muscle extracts from the Goto-Kakizaki...
(GK) rat model of type 2 diabetes (12). GK rats are spontaneously diabetic animals that exhibit chronically impaired insulin signaling (13,14), which usually occurs by 4 weeks of age (15). They are characterized by increased blood glucose levels without significant alterations in non-fasting plasma insulin levels (16). Diabetic GK skeletal muscles are characterized by a diminished recruitment of the glucose transporter isoform GLUT4 (17), membrane cytoskeletal defects in the dystrophin-dystroglycan complex (17,18), an inhibition of insulin receptor auto-phosphorylation (19), impaired activities of insulin signaling intermediates (20), abnormal mitochondrial functioning (21) and a reduced percentage of oxidative fibres (22). Since diabetic GK rats are non-obese, fundamental mechanisms of type 2 diabetes can be investigated without potentially complicating obesity-related factors.

The proteomic analysis of normal versus non-obese diabetic skeletal muscles presented herein has revealed a moderate differential expression pattern for 21 proteins, whereby 7 proteins were found to be reduced and 14 proteins to be increased in their abundance in GK tissue. With respect to neuromuscular disorders, the mass spectrometric cataloguing of normal muscle and the profiling of genetic and physiological animal models over the last few years have established large proteomic maps (23). Databanks of biomarkers that are implicated in muscular atrophy, fibre transformation, muscular dystrophy or age-related muscle wasting are now available for comparative biochemical studies (24). In this respect, the proteomic findings of this study agree with the idea that diabetes mellitus is associated with a generally perturbed metabolism and amino acid metabolism, as well as changes in the contractile apparatus, the anti-oxidant defense system, detoxification mechanisms and the cellular stress response.

Materials and methods

Materials. For the comparative gel electrophoretic analysis of normal versus diabetic muscle proteins, Immobiline pH gradient IPG dry strips, ampholytes, cover fluid and acetonitrile were purchased from Amersham Bioscience/GE Healthcare (Little Chalfont, Bucks, UK). Ultrapure Protogel acrylamide stock solutions were obtained from National Diagnostics (Atlanta, GA, USA). Gel electrophoretic buffer systems, protein molecular weight ladders and protein assay reagents were purchased from BioRad Laboratories (Hemel-Hempstead, Hertfordshire, UK). For the peptide mass spectrometric identification of muscle proteins, sequencing grade-modified trypsin was purchased from Promega (Madison, WI, USA). LC-MS Chromasolv water and formic acid were from Fluka (Milwaukee, WI, USA). The visualization of gel electrophoretically separated proteins, Coomassie Brilliant Blue G-250 dye was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Protease inhibitors were from Roche Diagnostics (Mannheim, Germany). All other analytical-grade chemicals were purchased from Sigma Chemical Company (Dorset, UK).

Animal model. As an internationally established animal model of type 2 diabetes, the spontaneous diabetic GK rat (12) was used in this study. In obesity-related diabetes, high levels of circulating free fatty acids and an extensive intramyocellular accumulation of triacylglycerol probably play a key role in causing decreased tissue sensitivity for insulin. However, since the GK rat is non-obese, the analysis presented herein eliminates to a large extent complicating factors due to excess lipids in muscle fibres and focuses instead on the core defects in a spontaneous form of type 2 diabetes. Rats were purchased from M&B Taconic Ltd. Animal Suppliers (Ry, Denmark). For comparative proteomic studies, the accessible protein complement was extracted from freshly dissected gastrocnemius muscles from 9-week-old normal Wistar rats and age-matched GK rats. The validation of the diabetic status of the cohort of GK rats used in this study has previously been documented (17). Non-fasting blood samples from GK rats showed a significant increase in glucose levels as compared to Wistar rats, but plasma insulin levels were relatively comparable between both rat strains. The average body weight of diabetic animals was found to be slightly below that of normal rats.

Preparation of total gastrocnemius muscle extracts. Muscle samples with a wet weight of 200 mg were quick-frozen in liquid nitrogen and ground into a fine powder using a mortar and pestle. The muscle powder was subsequently placed into 1 ml lysis buffer (7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 100 mM DTT and 2% (v/v) pH 3-10 ampholytes), which was supplemented with a protease inhibitor cocktail (25). Following incubation at room temperature for 3 h, the suspension was centrifuged at 14,000 x g for 20 min at 4°C. The total protein complement extracted from normal and diabetic tissues was quantified by the Bradford method (26).

Two-dimensional gel electrophoresis. Total muscle extracts from normal and diabetic muscle tissues were separated in the first dimension by isoelectric focusing and in the second dimension by sodium dodecyl sulphate polyacrylamide gel electrophoresis, as previously described (27,28). For the comparative proteomic analysis, 4 biological repeats of normal and 4 biological repeats of diabetic samples was used. Isoelectric focusing strips were rehydrated in rehydration buffer [7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 1.2% deStreak and 2% (v/v) pH 3-10 ampholytes] and 700 mg of muscle protein sample for 12 h. First-dimension protein separation was carried out on an Amersham IPGphor IEF system, following the manufacturer’s recommendations and the optimized protocol of our laboratory for the separation of skeletal muscle proteins (28). Following chemical reduction and alkylation by a standardized protocol (25), first-dimension strips were carefully placed on top of 12.5% (w/v) slab gels and electrophoresed in an Amersham Ettan DALT-Twelve system at 1.5 W per gel until the bromophenol blue dye front had just run off the gel. The protein separation pattern on two-dimensional gels was visualized by colloidal Coomassie Blue (29), silver (30) or fluorescent RuBPs (31) staining. High-resolution gel images where analysed with the Progenesis software programme from Non-Linear Dynamics (Newcastle upon Tyne, UK).

Mass spectrometric identification of muscle proteins. In order to unequivocally identify proteins of interest, the peptide mass
spectrometric analysis of muscle proteins with a changed abundance in diabetic muscle tissue was carried out on a Model 6430 Ion Trap LC/MS apparatus from Agilent Technologies (Santa Clara, CA, USA). Excision, washing, destaining and treatment with trypsin were performed by a previously optimised method (28). Trypsin-generated peptides were obtained by removing supernatants from digested gel plugs. Further recovery was achieved by adding 30% acetonitrile/0.2% trifluoroacetic acid to the gel plugs for 10 min at 37˚C with gentle agitation. Resulting supernatants were pooled with the initially recovered cohort of peptides following trypsin digestion.

Further peptide recovery was achieved through the addition of 60% acetonitrile/0.2% trifluoroacetic acid to each plug for 10 min at 37°C with gentle agitation. Supernatants were added to the peptide pool. The sample was dried through vacuum centrifugation and the concentrated peptide fractions were then resuspended in mass spectrometry-grade distilled water and 0.1% formic acid for identification by ion trap LC-MS analysis. Separation of peptides was performed with a nanoflow Agilent 1200 series system, equipped with a Zorbax 300SB C18 5 μm, 4 mm x 40 nl pre-column and an Zorbax 300SB C18 5 μm, 43 mm x 75 μm analytical reversed phase column using the HPLC-Chip technology (32).

Mobile phases utilized were A: 0.1% formic acid, B: 50% acetonitrile and 0.1% formic acid. Samples were loaded into the enrichment at a capillary flow rate set to 2 μl/min with a mix of A and B at a ratio 19:1. Tryptic peptide fragments were eluted with a linear gradient of 10-90% solvent B over 2 μl/min with a constant nano pump flow of 0.6 ml/min. A 1 min post-time of solvent A was used to remove sample carry over. The capillary voltage was set to 1700 V. The flow and the temperature of the drying gas were 4 l/min and 300°C, respectively (33). Database searches were carried out with Mascot MS/MS Ion search (Matrix Science, London, UK; MSDB database, release 20063108). All pI values and
Muscle-associated proteins with an increased abundance in diabetic skeletal muscle. Analytical two-dimensional gels were stained with colloidal Coomassie Blue and images from normal versus diabetic preparations compared with the help of a Typhoon Trio variable imager and Progenesis 2-D analysis software. Fig. 2 shows a reference gel of diabetic rat skeletal muscle used for the mass spectrometric identification of proteins with a differential expression profile. Muscle proteins with a changed abundance are marked by circles and are numbered 1-23. Protein species with a changed abundance in GK gastrocnemius muscle ranged in molecular mass from 15.9 kDa (Cu/Zn superoxide dismutase) to 67.6 kDa (dihydrolipoamide s-acetyltransferase of the pyruvate dehydrogenase complex) and covered a pI-range from pI 4.9 (ATP synthase) to pI 8.9 (ß-globin). A decreased expression was found in the case of 7 muscle proteins, and 16 proteins were shown to be increased in their abundance.

Mass spectrometric identification of proteins with a diabetes-associated change in abundance. ESI MS analysis was used to unequivocally identify protein species contained in two-dimensional spots with an altered density in normal versus diabetic preparations. A list of the 23 muscle-associated proteins that exhibited a significantly altered expression level in GK muscle is shown in Table I. The table summarizes MS-identified protein species listed in Table I correlate with the numbering of two-dimensional spots marked in Fig. 2. The majority of identified muscle proteins were found to be constituents of various metabolic pathways. This included enzymes and transporters involved in glycolysis, the citric acid cycle, oxidative phosphorylation, lipolytic catabolism, nucleotide metabolism, carbon dioxide removal, oxygen transportation, and amino acid catabolism. In addition, components of the contractile apparatus, the cellular stress response, anti-oxidant defense mechanisms and formaldehyde detoxification appear to be affected in diabetic muscle tissue.

Skeletal muscle proteins with diabetes-associated expression changes. The two muscle protein species with the highest fold decrease were identified as carbonic anhydrase isoform CA3 (spot 1) and 3-hydroxyisobutyrate dehydrogenase (spot 2). Other proteins with reduced expression level were found to be the E2 component of the 2-oxo-glutarate dehydrogenase complex (spot 3), enolase (spots 5 and 7) and esterase D (spot 6). Spots 4 and 8, which were both identified as mitochondrial ATP synthase, exhibited decreased and increased levels, respectively. These findings are difficult to interpret, but may be due to differential pathological effects on post-translational modifications in ATP synthase molecules. This might explain the opposite alterations in expression levels of two ATP synthase isoforms with differing isoelectric points and molecular masses.

Muscle-associated proteins with an increased abundance in GK muscle preparations were identified as adenylate kinase...
Table I. Protein species that exhibit a differential expression pattern in normal versus diabetic skeletal muscle extracts.

<table>
<thead>
<tr>
<th>Spot No.</th>
<th>Protein name</th>
<th>Peptide sequence</th>
<th>Accession no.</th>
<th>Isoelectric point (pI)</th>
<th>Molecular mass (kDa)</th>
<th>Peptides matched</th>
<th>Mascot score</th>
<th>Coverage (%)</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Carbonic anhydrase CA3</td>
<td>RGGPLSGPYRL RVVFDDTFDRS KTLNNGKTCRV KGDNQSPIELHTKD KEPMTVSSDQMAKL RSMRLGGLPSGPYRL RVVFDDTFDRSRLMRG KGDNQSPIELHTKD RIRIRHDPSLQPSVSYDPGSK</td>
<td>gi</td>
<td>3137748</td>
<td>6.9</td>
<td>29.7</td>
<td>9</td>
<td>45</td>
<td>29</td>
</tr>
<tr>
<td>2</td>
<td>3-Hydroxyisobutyrate dehydrogenase</td>
<td>KDLGLAQDSTSTKT KTPILGSVAHQQVYRM KEAGEQVASSPADVKA KMGAVFMDAPVSGVGAARS KKGSLIDSTIDPSVK KEAGEQVASSPADVKAADRI RITMLPSSNMIYVSANGILKK KDLGLAQDSTSTKTPIPPGVAHQQYRM</td>
<td>gi</td>
<td>556389</td>
<td>8.6</td>
<td>36.8</td>
<td>8</td>
<td>240</td>
<td>30</td>
</tr>
<tr>
<td>3</td>
<td>Dihydrolipoamide s-acetyltransferase</td>
<td>RTINELGEKA RGLVVPVIRN KLGMSAFVKA KVEGTPPTLTRLK KAKPAEAPATAGKA RNVEFMNYADIERT KASAFALQEPVAVIDDATKE</td>
<td>gi</td>
<td>19527000</td>
<td>8.9</td>
<td>49.2</td>
<td>7</td>
<td>142</td>
<td>17</td>
</tr>
<tr>
<td>4</td>
<td>ATP synthase, β subunit</td>
<td>KILQDYKSI KIGLFGGAGVGKT KVVDLLAPYAKG RQKVLDSGAPIKI RTIAMDGTEGLVRC RIMVIGEPIDERG KAHGGYSVFAGVGERTRVALTGLTVAYFRED</td>
<td>gi</td>
<td>1374715</td>
<td>4.9</td>
<td>51.2</td>
<td>18</td>
<td>341</td>
<td>55</td>
</tr>
<tr>
<td>Spot No.</td>
<td>Protein name</td>
<td>Peptide sequence</td>
<td>Accession no.</td>
<td>Isoelectric point (pI)</td>
<td>Molecular mass (kDa)</td>
<td>Peptides matched</td>
<td>Mascot score</td>
<td>Coverage (%)</td>
<td>Fold change</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>------------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>5</td>
<td>Enolase 3, β</td>
<td>KTVLIMELINVAKA</td>
<td>gill126723393l</td>
<td>7.1</td>
<td>47.3</td>
<td>32</td>
<td>817</td>
<td>65</td>
<td>-1.5</td>
</tr>
</tbody>
</table>

KTVLIMELINNVAKA
KVALVYQGMNEPPGARA
RLVLEVAQHLGESTVRT
RIMNVIGEPIDERGPIKT
RIMDPNIVGSEHYDVARG
KVLDSGAPIKPVGPETLGRI
RAIAELGIYPAVDPLDSTSR1
RFLSQPFQVAEVFTGIMGKL
KSLQDIAILGMDELSEEDKL
RIPSAGYQPTLATDMGTMQERI

KTVLIMELINNVAKA
KVALVYQGMNEPPGARA
RLVLEVAQHLGESTVRT
RIMNVIGEPIDERGPIKT
RIMDPNIVGSEHYDVARG
KVLDSGAPIKPVGPETLGRI
RAIAELGIYPAVDPLDSTSR1
RFLSQPFQVAEVFTGIMGKL
KSLQDIAILGMDELSEEDKL
RIPSAGYQPTLATDMGTMQERI

KYNQLMRIRIEEALGDKARYLGKGVLKAKLSVVDQEKV
KTLGPALESKK
KLSVVDQEKV
KTAQAAGYPDKV
RLAKYNQLMRI
RIGAEVHYHLKG
KFMIELDGTENKS
RGNPTVEVDLHTAKG
RGNPTVEVDLHTAKG
RIEEALGDKAVFAGRK
KFGANAILGVSLAVCA
KVVIQMDVAAESEFYN
RGNPTVEVDLHTAKGRF
KVNQIGSVTESIQACKL
KVDKFMIELDGTENKS
KAVEHINKTLGPALEKK
RAAVPSGASTGIYEALELRRD
KLAMQEFMLPVGASS0FKE
KLAMQEFMLPVGASSFKE
<table>
<thead>
<tr>
<th>Spot No.</th>
<th>Protein name</th>
<th>Peptide sequence</th>
<th>Accession no.</th>
<th>Isoelectric point (pl)</th>
<th>Molecular mass (kDa)</th>
<th>Peptides matched</th>
<th>Mascot score</th>
<th>Coverage (%)</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Esterase D formylglutathione hydrolase</td>
<td>KKFNYGLDPQDSKW KSGCQQAASEHGLVVIAPDTSRPG</td>
<td>gi</td>
<td>157823267</td>
<td>6.4 31.9 2 46 12 -1.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Enolase 1 (α)</td>
<td>KYNQILRI RIEEEILSGKA KLNVVEQEKI RIGAEVYHNKN RGNPTEVDYLTAKG RYITPDQLADLYKS KYNQIGSVTESLQACKL RAAVPSGASTGYEALELRD KLMQEMLIPVAGSFRE KDATNVGDEGFGPAFNLENEALRP KYGKDATNVGDEGFGPAFNLENEALRP RHIADLAGNPEVILPVPAEFVINGSHAGNKL</td>
<td>gi</td>
<td>157823267</td>
<td>6.2 47.5 12 225 35 -1.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>ATP synthase, β subunit</td>
<td>RTIAMDGTGEGLVRG KAHGGYSVAGVGERT RTIAMDGTGEGLVRGQKV RLVLEVAQHLGESTVRT RIMNVGEPIDERPIKT KVLDSGAIPKPVGTPLGRI RFLSQFPQVAEVFTGHMGKL REGNDLH EMIKE GINL</td>
<td>gi</td>
<td>1374715</td>
<td>4.9 51.2 8 157 21 +1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spot No.</td>
<td>Protein name</td>
<td>Peptide sequence</td>
<td>Accession no.</td>
<td>Isoelectric point (pI)</td>
<td>Molecular mass (kDa)</td>
<td>Peptides matched</td>
<td>Mascot score</td>
<td>Coverage (%)</td>
<td>Fold change</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
<td>------------------</td>
<td>---------------</td>
<td>------------------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>9</td>
<td>Adenylate kinase AK1</td>
<td>KIIFVVGPGSSGKG KATEPVISFYDKRG KYGYTHLSGDDLRA KDSSNGFLIDGYPRE KGELVPLETVLDMLRD KIAQPTLLLNYVDAGPETMTQRL RKIAQPTLLLNYVDAGPETMTQRL</td>
<td>gi</td>
<td>8918488l</td>
<td>7.7</td>
<td>21.7</td>
<td>7</td>
<td>184</td>
<td>50</td>
</tr>
<tr>
<td>10</td>
<td>Cu-Zn superoxide dismutase</td>
<td>RHVGDLGNAAGKD KDGVANVSIEDRV RVISLSGEHSIIGRT KGDPVQGVIHEEQKA</td>
<td>gi</td>
<td>203658l</td>
<td>5.9</td>
<td>15.9</td>
<td>4</td>
<td>155</td>
<td>32</td>
</tr>
<tr>
<td>11</td>
<td>Immunoglobulin light chain</td>
<td>KDSTYLSLSTLTLSDA RTVAAPSFIFPPDEQLKS KDVLQSGNSQESVTEQDSDK KDVLQSGNSQESVTEQDSDK</td>
<td>gi</td>
<td>243868l</td>
<td>8.5</td>
<td>25.9</td>
<td>4</td>
<td>114</td>
<td>22</td>
</tr>
<tr>
<td>12</td>
<td>Phosphoglucomutase 1</td>
<td>MVKIVTVKT KVDDLSGVGKQ RIAAAANGKRL RLIFADGSRK RMSPTSGALDRV RLSTGSGATIRL KDLEALMLRS KFFGNMDASKL KIALYTPTGWKFK KIIEEYACPDLCVK RYDYEEVEAEAGANKM KQFSAKDKVYTVEKA KTQAYPDQKPGTSGLRK KADNFEEKDPVDSISISN KLSLCEESFGTSGSHIRE RYDYEEVEAEAGANKMKRD KINQDPQVMLAPLISIALKVR</td>
<td>gi</td>
<td>77627971l</td>
<td>6.1</td>
<td>61.6</td>
<td>17</td>
<td>362</td>
<td>42</td>
</tr>
<tr>
<td>Spot No.</td>
<td>Protein name</td>
<td>Peptide sequence</td>
<td>Accession no.</td>
<td>Isoelectric point (pI)</td>
<td>Molecular mass (kDa)</td>
<td>Peptides matched</td>
<td>Mascot score</td>
<td>Coverage (%)</td>
<td>Fold change</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>------------------------</td>
<td>----------------------</td>
<td>------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>13</td>
<td>Coq 9 protein</td>
<td>KLVQLGQAEEKR RMLIPYIEHWPRA KSTGEALVQGLMGAAVTLKN RYTDQSGEEEDYESEEIQHRI</td>
<td>gi51259441l</td>
<td>5.5</td>
<td>35.1</td>
<td>4</td>
<td>76</td>
<td>19</td>
<td>+1.7</td>
</tr>
<tr>
<td>14</td>
<td>Dihydrolipoamide s-acetyltransferase (E2 component of pyruvate dehydrogenase complex)</td>
<td>RVFVSPLAKK KILVPVTRD KLIPADNEKG KDIDSFVPTKA KGRVFVSPLAKK KELNKMLLEGKG KAAPA AAAAPPPGPRV KYLKVPTMLL KIILTFQVKTGPEGRI RDVLGTPLCLIVKQ KVPLPSLSTMQAGTIARW RVAPTAVGIFIDIPSRR RVAPTAVGIFIDIPSRR RVKDIDSFVPTKAAPAAAAAPPGPRV</td>
<td>gi78365255l</td>
<td>8.8</td>
<td>67.6</td>
<td>14</td>
<td>121</td>
<td>21</td>
<td>+1.8</td>
</tr>
<tr>
<td>15</td>
<td>Isocitrate dehydrogenase 3 (NAD+) α</td>
<td>KAPIQWEERN RNVTAQGPGGKW KIEACFATIKD RHMLFDHAAGK KCSDFTEEICRKR KTPAAAGHPSMNLLRK KDMANPTALLLSAVMLRHR RNVTIAQGPGGKWMPKEAKE</td>
<td>gi16758446l</td>
<td>6.5</td>
<td>40.1</td>
<td>8</td>
<td>94</td>
<td>24</td>
<td>+1.9</td>
</tr>
<tr>
<td>16</td>
<td>Cytochrome c oxidase, subunit Va</td>
<td>RLNDFAVRI RRLNDFAVRI KGMNTLVGYDVLVPEPKI KGMNTLVGYDVLVPEPKI RGMNITLGVYDVLVPEPKI</td>
<td>gi24233541l</td>
<td>6.1</td>
<td>16.4</td>
<td>5</td>
<td>85</td>
<td>17</td>
<td>+1.9</td>
</tr>
</tbody>
</table>
Table I. Continued.

<table>
<thead>
<tr>
<th>Spot No.</th>
<th>Protein name</th>
<th>Peptide sequence</th>
<th>Accession no.</th>
<th>Isoelectric point (pI)</th>
<th>Molecular mass (kDa)</th>
<th>Peptides matched</th>
<th>Mascot score</th>
<th>Coverage (%)</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Capping protein (actin filament) muscle z-line, α 2</td>
<td>RLLLNNDNLLRE KEHYPNGVCTVYGKK KFTVTPSTTQVGVILKI KDIQDSLTVSNEVQTAKE KIQVHYYEDGNVQLVSHKD KFIHAPPGEFNEVFNDVRL REGAAHAFDAQYLDQFTPVK1 KEATDPRPYEAENAIERSWRT KIVEAAENETYQAISENYQTMSDITTFKA</td>
<td>gi</td>
<td>6671672</td>
<td></td>
<td>5.6</td>
<td>33.1</td>
<td>9</td>
<td>162</td>
</tr>
<tr>
<td>18</td>
<td>Actin α, skeletal muscle</td>
<td>KIAPPERSK KAGFGADDAPRA RDLTDLMLKI RDLTDLMLKI RGYFVTTAERE KEITALAPSTMKI RAVFFPSIVGRPH</td>
<td>gi</td>
<td>149043182</td>
<td></td>
<td>5.2</td>
<td>42.4</td>
<td>7</td>
<td>279</td>
</tr>
<tr>
<td>19</td>
<td>Heat shock protein Hsp27/B1</td>
<td>RQLSSGVSEIRQ RLFDQAFGVPFR RVSDDVNHFAPEELTVKT KAVTQRSEITIPVTFEARA KKYLLPGDVPTLVSSLPSGTLTVAPLPKAK RKYTLPGDVPTLVSSLPSGTLTVAPLPKAK</td>
<td>gi</td>
<td>204665</td>
<td></td>
<td>6.1</td>
<td>22.9</td>
<td>6</td>
<td>122</td>
</tr>
<tr>
<td>20</td>
<td>Fructose-bisphosphate aldolase A</td>
<td>RQLLLTADDRF KGLIAADEGTSIAKR KADDGRFPQVKS MHPYPALTPEQKK KCPILKPAWTFTSYGRA KIGEHTPSLAIMENANV LARY KIGEHTPSLAIMENANV LARY KGVVPLAGTNGETTQGDLGGLSER C KVDKGVVPLAGTNGETTQGDLGGLSER</td>
<td>gi</td>
<td>6978487</td>
<td></td>
<td>8.3</td>
<td>39.8</td>
<td>9</td>
<td>166</td>
</tr>
</tbody>
</table>
Table I. Continued.

<table>
<thead>
<tr>
<th>Spot No.</th>
<th>Protein name</th>
<th>Peptide sequence</th>
<th>Accession no.</th>
<th>Isoelectric point (pI)</th>
<th>Molecular mass (kDa)</th>
<th>Peptides matched</th>
<th>Mascot score</th>
<th>Coverage (%)</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Globulin, B</td>
<td>MVHLTDAEA KATVSGLWGVRLLVYPWTQYKVNA DNVGAEALGRLKEFTPCAQAFQKV KVVAGVASALAHKYH KFGDLSSASAIMGNPVKA</td>
<td>gi164448680l</td>
<td>8.9</td>
<td>16.1</td>
<td>9</td>
<td>159</td>
<td>59</td>
<td>+2.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KAVTNADNVGAEALGRLv RYFSKFGDLSSASAIMGNPVKA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>3-Mercaptopurivate sulfurtransferase</td>
<td>RFQVVDARA RRFQVVDARA RFQGTQPEPRD KLLDASWYLPKL RAQPEHVISQGRG RALVSAQWVAEAKS KTHDILENLDARR KTHDILENLDARRF KSPSEPAEFCQAQLDPSFIKT RDGIEPQHIGPSVNPTEFLSEGLES</td>
<td>gi20304123l</td>
<td>5.9</td>
<td>33.2</td>
<td>10</td>
<td>199</td>
<td>36</td>
<td>+2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RRFQVVDARA RFQGTQPEPRD KLLDASWYLPKL RAQPEHVISQGRG RALVSAQWVAEAKS KTHDILENLDARR KTHDILENLDARRF KSPSEPAEFCQAQLDPSFIKT RDGIEPQHIGPSVNPTEFLSEGLES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Monoglyceride lipase</td>
<td>RIDSSVLSRN RMVSDFQVFVRD KGAYLMESSPSQDKTG LTLPLLQGSADRL</td>
<td>gi19923092l</td>
<td>6.9</td>
<td>33.8</td>
<td>4</td>
<td>110</td>
<td>10</td>
<td>+2.8</td>
</tr>
</tbody>
</table>

*The normal versus the diabetic rat skeletal muscle proteome was stained with colloidal Coomassie Blue and differentially expressed proteins were identified by ESI-MS/MS analysis.*
isofrom AK1 (spot 9), Cu/Zn superoxide dismutase (spot 10), immunoglobulin light chain (spot 11), phosphoglucomutase 9 (spot 12), Coq 9 protein (spot 13), the E2 component of the pyruvate dehydrogenase complex (spot 14), isocitrate dehydrogenase (spot 15), cytochrome c oxidase (spot 16), capping protein of the actin filament (spot 17), α-actin (spot 18), stress protein Hsp27/B1 (spot 19), fructose-bisphosphate aldolase (spot 20), β-globulin (spot 21), and 3-mercaptothyruvate sulfurtransferase (spot 22). Interestingly, the muscle protein species with the highest fold increase was identified as the enzyme monoglyceride lipase (spot 23).

Silver- and RuBPs-stained protein candidates with diabetes-associated expression changes. Following the detailed MS-based identification of CBB-stained proteins, diabetes-related changes in the expression of silver- or fluorescent RuBPs-labelled proteins was carried out. Although larger numbers of total protein spots were visualized by these two methods, surprisingly no additional components with markedly higher fold changes were identified. Interestingly stained proteins with a lower abundance in GK muscle were found to be acyl-CoA dehydrogenase (gi|56541110|; pI 8.9; 70.8 kDa) and pyruvate kinase (gi|1675994|; pI 6.6; 57.8 kDa). Fluorescent RuBPs staining revealed reduced expression of malate dehydrogenase isoform MDH-1 (gi|37590235|; pI 6.6; 57.8 kDa) and pyruvate dehydrogenase complex (spot 14), isocitrate dehydrogenase (spot 12), Coq 9 protein (spot 13), the E2 component of the 2-oxoglutarate dehydrogenase complex in muscle mitochondria that participates in succinyl-CoA production (45), agrees with the idea of abnormal mitochondrial functioning in diabetes (46). However, other mitochondrial markers such as isocitrate dehydrogenase, cytochrome c oxidase and Coq 9 protein (47) were shown to be increased in GK muscle, possibly representing a compensatory mechanism to improve the oxidative capacity. This would agree with the increased level of β-globulin.

Diabetes mellitus and its associated complications affect millions of patients worldwide, causing blindness, cardiovascular disease, kidney failure, stroke and skeletal muscular weakness (41). Older adults with type 2 diabetes exhibit significantly reduced muscle strength (7), which is thought to be a major contributor to the development of physical disability in the senescent population (42). These clinical facts clearly warrant detailed biochemical investigations into the molecular and cellular mechanisms that underlie abnormal hormone signalling in diabetic muscle tissue. Insulin resistance in peripheral organ systems, representing one of the main features of diabetes-related dysregulation, is believed to be already present at a very early stage of the pre-diabetic state (10).

In early type 2 diabetes, low levels of insulin resistance can probably be partially compensated by increased secretion levels via enhanced pancreatic β-cell activity. However, at more advanced stages of diabetes, β-cell failure occurs leading to inadequate amounts of circulating insulin to overcome defects in tissue sensitivity (8). Since type 2 diabetes is an extremely complex and heterogeneous disorder (2), and probably involves both genetic and environmental factors, an unbiased global analysis of diabetic tissues by proteomics should be useful to identify novel indicators of its molecular pathogenesis. In this respect, the mass spectrometry-based proteomic survey of diabetic skeletal muscle tissue presented herein has successfully revealed a variety of expression changes in key muscle proteins. However, as compared to more severe muscular defects (23,24), the diabetes-related expression changes of metabolic enzymes is relatively moderate.

The proteomic analysis of GK muscles indicates that abundant enzymes, transporters and structural components are affected in the non-obese diabetic phenotype. This includes muscle-associated proteins involved in glycolysis, the citric acid cycle, oxidative phosphorylation, lipolytic catalysis, nucleotide metabolism, carbon dioxide removal, oxygen transportation, amino acid catalysis, the contractile apparatus, cellular detoxification mechanisms and the stress response. The muscle protein species with the highest fold decrease were identified as 3-hydroxy-isobutyrate dehydrogenase and carbonic anhydrase CA3. Hydroxy-isobutyrate dehydrogenase is involved in a rate-limiting step of the degradation of valine, leucine and isoleucine (43). The resulting carbon skeleton can be utilized as a metabolic substrate for the generation of energy, and this mechanism appears to be weakened in diabetic muscle tissues. Interestingly, the CO2-removal mechanism and a specific detoxification mechanism seem to be affected in GK muscles. Since the muscle-specific isoform CA3 of carbonic anhydrase catalyses the vital conversion of CO2 into carbonic acid (44), its reduced expression suggests an impaired removal of CO2 in diabetic fibres.

In addition, a decreased concentration of esterase D formylglutathione hydrolase might cause toxic side effects. The reduced expression of dihydrodipoamide succinyltransferase, the core enzyme of the 2-oxoglutarate dehydrogenase complex in muscle mitochondria that participates in succinyl-CoA production (45), agrees with the idea of abnormal mitochondrial functioning in diabetes (46). However, other mitochondrial markers such as isocitrate dehydrogenase, cytochrome c oxidase and Coq 9 protein (47) were shown to be increased in GK muscle, possibly representing a compensatory mechanism to improve the oxidative capacity. This would agree with the increased level of β-globulin.

Diabetes seems to have a differential effect on key enzymes of the glycolytic pathway. While enolase levels were shown to be decreased, phosphoglucomutase and aldolase exhibited an elevated concentration in GK muscles. Since many glycolytic enzymes are multi-functional, it is difficult to interpret how insulin resistance triggers these altered expression patterns. However, changed abundance in these enzymes will certainly alter the glycolytic flux in diabetic muscle. Interestingly, pyruvate dehydrogenase, the key linker enzyme that connects glycolysis with the citric acid cycle, is elevated. This might be a compensatory mechanism in glucose-starved diabetic muscle tissues and might help to maximise the transformation of glycolysis-derived pyruvate into acetyl-CoA. In analogy to a recent proteomic survey of obese muscle (48), the AK1 isofrom of adenylate kinase is increased in diabetes, suggesting alterations in nucleotide metabolism. Higher concentrations of the contractile elements α-actin and the capping protein of the actin filament indicate diabetes-dependent repair mechanisms of the thin filament. This would agree with increased levels of stress proteins and anti-oxidant markers, such as the small heat shock protein Hsp27/B1, 3-mercaptothryuvate sulfurrtransferase and Cu/Zn superoxide dismutase. Their up-regulation demonstrates a considerable need to counter-act cellular damage due to diabetes. The protein species with the highest fold increase in GK muscle was identified as monoglyceride lipase. This enzyme...
mediates a critical step in the hydrolysis of stored triglycerides (49) and its up-regulation might represent increased energy utilization by the lipolytic pathway in glucose-starved muscle tissues. More detailed biochemical studies have to be carried out to determine the general suitability of monoglyceride lipase as a muscle marker of non-obese diabetes. However, it is clear that insulin resistance results in a lack of glucose uptake by muscle cells, which in turn has an effect on other metabolic pathways such as gluconeogenesis, triacylglycerol hydrolysis, fatty acid oxidation and ketone body formation.

In conclusion, this initial study of changes in the protein expression pattern of GK muscle has identified interesting new candidates for the establishment of a biomarker signature of diabetic skeletal muscle. It will now be critical to correlate these findings to investigations on human skeletal muscle (50-52) and to conduct more detailed studies with other protein dyes that exhibit a different dynamic labelling range, such as fluorescent methodologies (53). In the future, new signature molecules will hopefully be useful for the improvement of diagnostic methods and the identification of superior therapeutic targets to eliminate diabetes-associated muscle weakness.

 Acknowledgements

Research was supported by a project grant from the Irish Health Research Board (HRB-RP/2005/3), a Hume Scholarship from NUI Maynooth and an equipment grant from the Higher Education Authority (HEA-ERGGS-07-NUI). The authors thank Ms. Caroline Batchlor (NUI Maynooth) for assistance with mass spectrometry.

 References